FCM Versus R-FCM Followed by R-Maintenance or Observation Only

Inclusion Criteria

• patients with histologically proven stage III/IV centroblastic/centrocytic (FL),centrocytic (MCL)or lymphoplasmacytoid lymphoma (LPIC).
• relapsed disease after initial chemotherapy or peripheral blood stem celltransplantation
• two-dimensionally measurable lesion outside a previously irradiated area (osteoblasticbone lesions, ascites, and pleural effusions are not evaluable)
• age > 18 years
• Karnofsky-index > 60
• life expectancy of at least 3 months
• effective contraception in female premenopausal patients
• patient's written informed consent

Exclusion Criteria:

• age < 18 years
• Karnofsky-index < 60
• treatment with fludarabine or mitoxantrone within the preceding three months
• active auto-immune hemolytic anemia at the start of FCM chemotherapy
• participation in another clinical trial during the last 4 weeks
• participation in this study before
• previous treatment with murine antibodies
• concurrent diseases which exclude the administration of therapy as outlined by thestudy protocol
• non-compensated heart failure
• dilatative cardiomyopathy
• coronary heart disease with ST segment depression in ECG
• myocardial infarction during the last 6 months
• chronic lung disease with hypoxemia
• severe non-compensated hypertension
• severe non-compensated diabetes mellitus
• renal insufficiency (creatinine > 2.0 mg/dl), not related to lymphoma
• hepatic insufficiency with transaminase values greater than 3-fold of normal valuesand/or bilirubin levels > 2.0 mg/dl, not related to lymphoma
• clinical signs of cerebral dysfunction
• women during lactation or pregnancy or of childbearing potential not using a reliablecontraceptive method
• severe psychiatric disease
• serological positivity for HBV, HCV, HIV
• previous organ transplantation other than autologous peripheral blood stem celltransplantation
• missing written informed consent or missing written consent for data protection